ATyr Pharma

ATyr Pharma

Logo of ATyr Pharma

ATyr Pharma is a biotechnology company focused on the discovery and development of innovative medicines based on novel biological pathways. The company is headquartered in San Diego, California, and it specializes in the research of tRNA synthetase biology and its applications in treating various diseases.

History

ATyr Pharma was founded in 2005 by Dr. Paul Schimmel, a renowned scientist in the field of tRNA synthetase biology. The company was established to explore the therapeutic potential of proteins derived from tRNA synthetases, which are enzymes that play a crucial role in the translation of genetic information into proteins.

Research and Development

ATyr Pharma's research focuses on a class of proteins known as Physiocrines, which are derived from tRNA synthetases. These proteins have been found to have diverse biological functions, including roles in immune modulation, tissue regeneration, and inflammation. The company is investigating these proteins as potential treatments for a variety of diseases, including pulmonary disease, cancer, and autoimmune disorders.

Pipeline

The company's lead therapeutic candidate is ATYR1923, a fusion protein that targets the neuropilin-2 (NRP2) receptor. ATYR1923 is being developed for the treatment of interstitial lung diseases, including pulmonary sarcoidosis and other forms of fibrosis.

Collaborations

ATyr Pharma has established collaborations with several academic institutions and research organizations to advance its scientific discoveries. These partnerships aim to enhance the understanding of tRNA synthetase biology and accelerate the development of new therapeutic approaches.

Corporate Structure

The company is led by a team of experienced executives and scientists with expertise in biotechnology and drug development. ATyr Pharma is publicly traded on the NASDAQ stock exchange under the ticker symbol "LIFE."

Related pages

• Biotechnology
• tRNA synthetase
• Drug development
• Pulmonary disease